BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27601598)

  • 1. Direct Mapping of Additional Modifications on Phosphorylated O-glycans of α-Dystroglycan by Mass Spectrometry Analysis in Conjunction with Knocking Out of Causative Genes for Dystroglycanopathy.
    Yagi H; Kuo CW; Obayashi T; Ninagawa S; Khoo KH; Kato K
    Mol Cell Proteomics; 2016 Nov; 15(11):3424-3434. PubMed ID: 27601598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDP-glycerol inhibits the synthesis of the functional
    Imae R; Manya H; Tsumoto H; Osumi K; Tanaka T; Mizuno M; Kanagawa M; Kobayashi K; Toda T; Endo T
    J Biol Chem; 2018 Aug; 293(31):12186-12198. PubMed ID: 29884773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent Advances in α-dystroglycanopathy].
    Kuga A; Kanagawa M; Toda T
    Brain Nerve; 2011 Nov; 63(11):1189-95. PubMed ID: 22068471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression in retinal neurons of fukutin and FKRP, the protein products of two dystroglycanopathy-causative genes.
    Haro C; Uribe ML; Quereda C; Cruces J; Martín-Nieto J
    Mol Vis; 2018; 24():43-58. PubMed ID: 29416295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structures of fukutin-related protein (FKRP), a ribitol-phosphate transferase related to muscular dystrophy.
    Kuwabara N; Imae R; Manya H; Tanaka T; Mizuno M; Tsumoto H; Kanagawa M; Kobayashi K; Toda T; Senda T; Endo T; Kato R
    Nat Commun; 2020 Jan; 11(1):303. PubMed ID: 31949166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Muscular Dystrophy Gene TMEM5 Encodes a Ribitol β1,4-Xylosyltransferase Required for the Functional Glycosylation of Dystroglycan.
    Manya H; Yamaguchi Y; Kanagawa M; Kobayashi K; Tajiri M; Akasaka-Manya K; Kawakami H; Mizuno M; Wada Y; Toda T; Endo T
    J Biol Chem; 2016 Nov; 291(47):24618-24627. PubMed ID: 27733679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell endogenous activities of fukutin and FKRP coexist with the ribitol xylosyltransferase, TMEM5.
    Nishihara R; Kobayashi K; Imae R; Tsumoto H; Manya H; Mizuno M; Kanagawa M; Endo T; Toda T
    Biochem Biophys Res Commun; 2018 Mar; 497(4):1025-1030. PubMed ID: 29477842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycosylation with ribitol-phosphate in mammals: New insights into the O-mannosyl glycan.
    Manya H; Endo T
    Biochim Biophys Acta Gen Subj; 2017 Oct; 1861(10):2462-2472. PubMed ID: 28711406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 160 kb deletion in ISPD unmasking a recessive mutation in a patient with Walker-Warburg syndrome.
    Czeschik JC; Hehr U; Hartmann B; Lüdecke HJ; Rosenbaum T; Schweiger B; Wieczorek D
    Eur J Med Genet; 2013 Dec; 56(12):689-94. PubMed ID: 24120487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCYT2 synthesizes CDP-glycerol in mammals and reduced PCYT2 enhances the expression of functionally glycosylated α-dystroglycan.
    Imae R; Manya H; Tsumoto H; Miura Y; Endo T
    J Biochem; 2021 Oct; 170(2):183-194. PubMed ID: 34255834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of a novel monoclonal antibody against truncated glycoforms of α-dystroglycan lacking matriglycans.
    Yamasaki F; Umezawa F; Sensui T; Anzo M; Abo H; Kuo CW; Khoo KH; Kato K; Yagi H; Kawashima H
    Biochem Biophys Res Commun; 2021 Nov; 579():8-14. PubMed ID: 34583196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto α-dystroglycan.
    Gerin I; Ury B; Breloy I; Bouchet-Seraphin C; Bolsée J; Halbout M; Graff J; Vertommen D; Muccioli GG; Seta N; Cuisset JM; Dabaj I; Quijano-Roy S; Grahn A; Van Schaftingen E; Bommer GT
    Nat Commun; 2016 May; 7():11534. PubMed ID: 27194101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of α-dystroglycan.
    Kuga A; Kanagawa M; Sudo A; Chan YM; Tajiri M; Manya H; Kikkawa Y; Nomizu M; Kobayashi K; Endo T; Lu QL; Wada Y; Toda T
    J Biol Chem; 2012 Mar; 287(12):9560-7. PubMed ID: 22270369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic aspects of the formation of α-dystroglycan and therapeutic research for the treatment of α-dystroglycanopathy: A review.
    Taniguchi-Ikeda M; Morioka I; Iijima K; Toda T
    Mol Aspects Med; 2016 Oct; 51():115-24. PubMed ID: 27421908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Missense mutations in β-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) cause Walker-Warburg syndrome.
    Buysse K; Riemersma M; Powell G; van Reeuwijk J; Chitayat D; Roscioli T; Kamsteeg EJ; van den Elzen C; van Beusekom E; Blaser S; Babul-Hirji R; Halliday W; Wright GJ; Stemple DL; Lin YY; Lefeber DJ; van Bokhoven H
    Hum Mol Genet; 2013 May; 22(9):1746-54. PubMed ID: 23359570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AGO61-dependent GlcNAc modification primes the formation of functional glycans on α-dystroglycan.
    Yagi H; Nakagawa N; Saito T; Kiyonari H; Abe T; Toda T; Wu SW; Khoo KH; Oka S; Kato K
    Sci Rep; 2013 Nov; 3():3288. PubMed ID: 24256719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muscular Dystrophy with Ribitol-Phosphate Deficiency: A Novel Post-Translational Mechanism in Dystroglycanopathy.
    Kanagawa M; Toda T
    J Neuromuscul Dis; 2017; 4(4):259-267. PubMed ID: 29081423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prenatal muscle development in a mouse model for the secondary dystroglycanopathies.
    Kim J; Hopkinson M; Kavishwar M; Fernandez-Fuente M; Brown SC
    Skelet Muscle; 2016; 6():3. PubMed ID: 26900448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The functional O-mannose glycan on α-dystroglycan contains a phospho-ribitol primed for matriglycan addition.
    Praissman JL; Willer T; Sheikh MO; Toi A; Chitayat D; Lin YY; Lee H; Stalnaker SH; Wang S; Prabhakar PK; Nelson SF; Stemple DL; Moore SA; Moremen KW; Campbell KP; Wells L
    Elife; 2016 Apr; 5():. PubMed ID: 27130732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome.
    Willer T; Lee H; Lommel M; Yoshida-Moriguchi T; de Bernabe DB; Venzke D; Cirak S; Schachter H; Vajsar J; Voit T; Muntoni F; Loder AS; Dobyns WB; Winder TL; Strahl S; Mathews KD; Nelson SF; Moore SA; Campbell KP
    Nat Genet; 2012 May; 44(5):575-80. PubMed ID: 22522420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.